Concurrent Cetuximab and Nivolumab as a Second-Line or beyond Treatment of Patients with Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results of Phase I/II Study

SIMPLE SUMMARY: To improve overall survival (OS), we evaluated a combination of cetuximab and nivolumab for toxicity and efficacy in patients with incurable recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC). In addition, electronic health record-derived real-world data were u...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Christine H., Bonomi, Marcelo, Steuer, Conor E., Li, Jiannong, Bhateja, Priyanka, Johnson, Matthew, Masannat, Jude, Song, Feifei, Hernandez-Prera, Juan C., Wenig, Bruce M., Molina, Helen, Farinhas, Joaquim M., McMullen, Caitlin P., Wadsworth, J. Trad, Patel, Krupal B., Kish, Julie A., Muzaffar, Jameel, Kirtane, Kedar, Rocco, James W., Schell, Michael J., Saba, Nabil F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967147/
https://www.ncbi.nlm.nih.gov/pubmed/33803335
http://dx.doi.org/10.3390/cancers13051180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967147/
https://www.ncbi.nlm.nih.gov/pubmed/33803335
http://dx.doi.org/10.3390/cancers13051180

Ejemplares similares